Inceptua announced today that Stefan Fraenkel has been appointed CEO effective 1 January 2020. Alan Raffensperger is appointed Executive Vice-Chairman of the Inceptua Group.

Inceptua – a pharmaceutical company and service partner spanning throughout the product lifecycle – from comparator sourcing for clinical trials, through early access programs to licensing and commercialization of products, today announces that Stefan Fraenkel, Executive Vice President, and Member of the Executive Leadership Team, is promoted to CEO effective 1 January 2020. Since 2017 Stefan has been leading the creation of one of the company’s three business units, Inceptua Pharma.

Stefan Fraenkel says:
“I’m both humbled and proud to get this opportunity as we are growing and transforming Inceptua to further strengthen our position. I look forward to working closely with all parts of our business and competent teams to further develop Inceptua and help realize our ambition to be a global partner of choice for providing critical treatments to patients in need.”

Chairman of the Board, Peter Krantz, says:
“Stefan is an accomplished executive with a strong industry background focusing on commercial deal making, global marketing and sales, and corporate development. I look forward to continue the collaboration with Stefan in his new role as CEO as we take Inceptua to the next level.”

Stefan holds an MBA and a Ph.D. in international economics and came to Inceptua from Swedish Orphan Biovitrum AB (publ) (Sobi™) where he until 2017 served as Head of Corporate Development and held senior management positions in marketing and sales. Prior to Sobi, Stefan worked at Wyeth/Pfizer where he held various international commercial leadership positions in Europe and in the USA.

Alan Raffensperger joins the Board of Directors
In parallel with the appointment of a new CEO, Inceptua announces that Alan Raffensperger will join the Board of Directors as Executive Vice-Chairman:

“As we are growing our company there is a need to further formalize our Board structure. As such we are delighted to announce that Alan Raffensperger will join the Inceptua Board of Directors. During his tenure as CEO, Alan has successfully led Inceptua to where we are today – strongly positioned as a pharmaceutical company and leading service partner spanning throughout the product lifecycle.  Over the past two years we have diversified our clinical trial services business, accelerated our early access program portfolio, and firmly established Inceptua Pharma. Alan will continue to play an active role in support of our business,” says Peter Krantz.

About Inceptua
Inceptua is a pharmaceutical company and service partner spanning throughout the product lifecycle – from comparator sourcing for clinical trials, through early access programs to licensing and commercialization of products.

We partner with life science companies of all sizes, drawing on over 20 years of industry experience. Our pharma and biotech offering includes registration and commercialization of products through in-licensing and flexible partnerships. We have leading expertise in strategy and operational implementation of pre-approval access programs making pharmaceutical products under clinical development available for patients and Inceptua’s clinical trial services business offers high quality clinical comparator sourcing and manufacturing services with an agile global supply chain to ensure that products are delivered exactly when needed.

Inceptua has global operations with local offices across Europe, USA, and Asia. www.inceptua.com

   Left-right: Stefan Fraenkel, CEO & Alan Raffensperger, EVC Inceptua